TARGETED ALPHA THERAPY CANDIDATE: RECRUITMENT COMPLETED FOR BLADDER CANCER STUDY
Telix (Melbourne, Australia) and Nantes-based company ATONCO S.A.S. (‘ATONCO’) today announced that the last patient has been treated in a…
News
Discover our latest news, innovations and advances in alpha-immunotherapy.
📰 Filter:
-
-
IONETIX AND ATONCO SIGN PARTNERSHIP AGREEMENT TO FIGHT BLADDER CANCER
Atonco (Nantes-Saint Herblain, France) and Ionetix (Lansing, MI, USA) have signed a partnership agreement to ensure GMP manufacturing and supply…
-
FIRST PATIENT RECEIVES DOSE IN TARGETED ALPHA THERAPY FEASIBILITY STUDY FOR BLADDER CANCER
Atonco announces that a first patient has been dosed in the Phase I ‘PERTINENCE’ study of TLX250-CDx in patients with…
-
ATONCO AND ICO NANTES ANGERS: CLINICAL PARTNERS IN THE FIGHT AGAINST CANCER
ATONCO S.A.S. (‘ATONCO’) today announces that it has entered into a clinical research partnership agreement with the Institut de Cancérologie…
-
ATONCO ANNOUNCES THE APPOINTMENT OF ADRIEN REYMOND AS DIRECTOR OF REGULATORY AFFAIRS AND QUALITY ASSURANCE
Atonco today announces that Adrien Reymond, PharmD, B.Eng and EMBA candidate, will lead regulatory affairs and quality. Adrien brings 15…
-
ATONCO ANNOUNCES THE APPOINTMENT OF SYLVAIN FANIER AS NEW CHAIRMAN OF ATONCO
Atonco today announces that Sylvain Fanier, MSc. EMBA, will succeed Professor Jean-François Chatal as Chairman effective March 16, 2020. Sylvain…
-
TELIX PARTNERS WITH FRENCH COMPANY ATONCO TO FIGHT BLADDER CANCER
Australian biopharmaceutical company Telix Pharmaceuticals Limited (ASX: TLX) has signed an agreement with French company ATONCO S.A.S. to study the…